The use of CRISPR–Cas9 may also facilitate the conduction of high-throughput screenings targeting biological components that play a crucial role in the prolifera­tion of cancer cells [63]. From a methodological perspective, the construction of a gene library consisting of single-guide sequences facilitates the targeted suppres­sion of a substantial number of genes within a single experimental setup. The gene library was subjected to incubation together with the required equipment, leading to the integration of the single-guide sequences into the cells and the targeted suppres­sion of a signicant percentage of them. After a phase of expansion, the procedure of DNA sequencing is carried out for the purpose of ascertaining the proportional occurrence of sequences that match those present in the sequence library. In contrast to the baseline controls, a reduction in the abundance of a certain gene sequence signies genes that have undergone negative selection and are hence crucial for the survival of cells [63]. Numerous research endeavors using this technological approach have explored a wide range of gene-associated results, including medica­tion resistance [64], cancer metastasis [65], and immune response [66]. A compre­hensive screening of the LNCaP cell line has been conducted in the context of prostate cancer, using a single-guide RNA library that specically targets over 19,000 genes. The ndings from this study, in conjunction with further mechanistic investigations, have shown that a cluster of genes encoding RNA-binding proteins, including those involved in alternative splicing and the regulation of the androgen receptor, plays a crucial role in the proliferation of LNCaP PCa cells [67]. In addi­tion, a recent study using a CRISPR screen identied novel pathways of resistance to inhibition of PARP, which may have implications for the therapy of metastatic PCa [68].